Please assess the completion status of the following clinical trial:

Trial Title: Tropical Influenza Control Strategies for the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥65 years on the day of inclusion~2. No influenza vaccination in the previous 10 months~3. No tetanus, diphtheria or pertussis vaccine in the previous 1 year~4. No virologically confirmed influenza infection in the previous 10 months~5. Able to provide written informed consent~6. Able to attend all scheduled visits and comply with all trial procedures~Exclusion Criteria:~1. Participation in the 4 weeks preceding the first trial vaccination or participation during the present trial period in another trial investigating a vaccine, drug, medical device, or medical procedure~2. History of a life threatening reaction to the vaccine used in the trial, or to a vaccine containing any of the same substances~3. Known systemic hypersensitivity to any of the vaccine components, including:~   * Egg protein (eggs or egg products)~  * Chicken products~  * Formaldehyde~  * Neomycin or kanamycin~  * Octoxinol 9 (Triton X-100)~  * Cetyltrimethylammonium bromide (CTAB)~4. History of Guillain-Barré syndrome (GBS) within 6 weeks following previous influenza vaccination~5. Acute respiratory infection on the day of enrolment~6. Moderate or severe acute illness/infection (according to investigator judgement) on the day of vaccination, or febrile illness (temperature ≥ 37.5°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.~7. Self-reported thrombocytopenia, contraindicating Intramuscular vaccination~8. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding six months; or long-term systemic corticosteroid therapy (prednisolone ≥ 7.5mg/day or equivalent for more than 2 consecutive weeks within the past 3 months)~9. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~10. Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~11. Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures in the opinion of the Investigator

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Six-monthly influenza vaccine (Type: EXPERIMENTAL): Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
- Annual influenza vaccine (Type: ACTIVE_COMPARATOR): Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete